Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV) - Full Text View

Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

This study has been suspended.

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00065572

Purpose

The purpose of this study is to assess the biological activity of ZD6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage IV).

Condition	Intervention	Phase
Carcinoma, Renal Cell Kidney Neoplasms	Drug: ZD6126 Drug: Placebo	Phase II

MedlinePlus related topics:

Cancer Kidney Cancer

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Newly diagnosed metastatic renal cell carcinoma
Suitable for nephrectomy

Exclusion Criteria:

Prior chemotherapy, biological therapy or radiation therapy for renal cell carcinoma or within the last 3 years for any other cancer
Significant cardiac event within 3 months of entry
Any history of coronary angioplasty or history of myocardial infarction

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00065572

Locations


United States, California
	Research Site
	Los Angeles, California, United States

United States, Delaware
	Research Site
	Newark, Delaware, United States

United States, Florida
	Research Site
	Tampa, Florida, United States

United States, Illinois
	Research Site
	Chicago, Illinois, United States

United States, Indiana
	Research Site
	Indianapolis, Indiana, United States

United States, Maryland
	Research Site
	Baltimore, Maryland, United States

United States, Missouri
	Research Site
	St. Louis, Missouri, United States

United States, New Hampshire
	Research Site
	Lebanon, New Hampshire, United States

United States, New Jersey
	Research Site
	Hackensack, New Jersey, United States

United States, New York
	Research Site
	Rochester, New York, United States
	Research Site
	Bronx, New York, United States

United States, Ohio
	Research Site
	Cleveland, Ohio, United States

United States, Oregon
	Research Site
	Portland, Oregon, United States

United States, Pennsylvania
	Research Site
	Philadelphia, Pennsylvania, United States

United States, Tennessee
	Research Site
	Nashville, Tennessee, United States

United States, Utah
	Research Site
	Salt Lake City, Utah, United States

Sponsors and Collaborators

AstraZeneca

More Information

Study ID Numbers:	D2820C00018, 6126IL/00018
First Received:	July 28, 2003
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00065572
Health Authority:	United States: Food and Drug Administration

Keywords provided by AstraZeneca:

Kidney Cancer

Metastatic

Newly diagnosed renal cell carcinoma

Study placed in the following topic categories:

Urologic Diseases

Kidney Neoplasms

Carcinoma, Renal Cell

Urogenital Neoplasms

Renal cancer

Kidney Diseases

Kidney cancer

Urologic Neoplasms

Adenocarcinoma

Urinary tract neoplasm

Neoplasms, Glandular and Epithelial

Carcinoma

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Site

Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on October 17, 2008